Tahara, Shigeyuki
Otsuka, Fumio
Endo, Takaaki
Funding for this research was provided by:
Novo Nordisk Pharma
Article History
Received: 16 May 2023
Accepted: 25 September 2023
First Online: 24 October 2023
Declarations
:
: Shigeyuki Tahara has received payment for lectures and presentations from Novo Nordisk, Pfizer, and JCR Pharmaceuticals. Fumio Otsuka has received contracts from Novo Nordisk and grants from Pfizer and Eli Lilly, as well as payment for lectures from Novo Nordisk, Pfizer, Eli Lilly, and JCR Pharmaceuticals. Takaaki Endo is an employee and holds stock at Novo Nordisk Pharma Ltd. Medical writing support for this manuscript was funded by Novo Nordisk Pharma Ltd.
: The study was conducted in accordance with the protocol, the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines (ICH), and other applicable laws and regulations of Japan, as appropriate. The study was approved by the Ethics Committee of Saga Memorial Hospital.